PDSS2 Antibody

What is PDSS2 and what biological functions does it serve?

PDSS2 is a heterotetrameric enzyme that catalyzes the condensation of farnesyl diphosphate (FPP) with isopentenyl diphosphate (IPP) to produce prenyl diphosphates of varying chain lengths. It plays a crucial role in the determination of the side chain of ubiquinone by supplying nona and decaprenyl diphosphate, which are precursors for the side chains of ubiquinone-9 (Q9) and ubiquinone-10 (Q10) respectively. The enzyme sequentially adds isopentenyl diphosphate molecules to farnesyl diphosphate with trans stereochemistry. Beyond its enzymatic function, PDSS2 may be involved in cerebellar development and regulation of mitochondrial respiratory chain function . In certain cancer contexts, full-length PDSS2 has demonstrated tumor-suppressive properties, affecting cell proliferation, migration, and invasion capabilities .

What applications are PDSS2 antibodies suitable for?

PDSS2 antibodies have been validated for multiple applications in molecular and cellular biology research. Commercially available antibodies are suitable for Western blotting (WB), which allows for protein quantification and molecular weight confirmation; immunohistochemistry on paraffin-embedded sections (IHC-P), enabling localization studies in tissues; and immunocytochemistry/immunofluorescence (ICC/IF), which reveals subcellular localization in cultured cells . Specialized PDSS2 antibodies have also been validated for flow cytometry (FACS) and ELISA applications . When selecting an antibody, researchers should verify the specific applications for which each antibody has been validated, as performance can vary considerably between applications even for the same antibody.

What are the key considerations when selecting a PDSS2 antibody?

When selecting a PDSS2 antibody, researchers should consider:

• Species reactivity: Verify that the antibody recognizes PDSS2 in your experimental species. Available antibodies have been validated for human, mouse, rat, and monkey samples .

• Clonality: Both polyclonal and monoclonal antibodies are available. Polyclonal antibodies may offer broader epitope recognition but potentially lower specificity, while monoclonal antibodies (e.g., clone 1D12) provide consistent results with high specificity to a single epitope .

• Validated applications: Ensure the antibody has been validated for your specific application (WB, IHC, ICC/IF, ELISA, or FACS) .

• Immunogen information: Consider the immunogen used to generate the antibody. For instance, some antibodies target the C-terminal region (aa 300 to C-terminus) of human PDSS2 .

• Validation data: Review the available validation data, including predicted band size (44 kDa for PDSS2) and tested cell lines or tissues .

How should PDSS2 antibodies be optimized for immunohistochemistry?

For optimal immunohistochemistry results with PDSS2 antibodies, follow this methodological approach:

• Fixation and processing: Use paraformaldehyde (PFA) fixation for tissues. Studies have successfully employed paraffin embedding for human tissues .

• Antigen retrieval: Heat-induced epitope retrieval is typically required for paraffin sections. The specific buffer should be optimized, but citrate buffer (pH 6.0) is often appropriate.

• Blocking and antibody concentration: For paraffin-embedded human colon tissue, successful staining has been achieved using a 1/200 dilution of antibody ab251797 . For other tissues, optimization may be required by testing a concentration range (typically 1-10 μg/ml).

• Detection system: Use a detection system appropriate for the host species of your primary antibody (typically rabbit for many PDSS2 antibodies). HRP-conjugated secondary antibodies with DAB substrate provide good results for brightfield microscopy.

• Controls: Always include positive controls (tissues known to express PDSS2, such as colon) and negative controls (primary antibody omission or isotype control) to validate staining specificity.

What is the recommended protocol for Western blotting with PDSS2 antibodies?

For Western blotting with PDSS2 antibodies, follow these evidence-based protocols:

• Sample preparation: Prepare whole cell lysates using standard RIPA buffer supplemented with protease inhibitors. Cell lines validated for PDSS2 detection include NIH/3T3 (mouse embryo fibroblast), NBT-II, RT4 (human urinary bladder cancer), and U-251 MG (human brain glioma) .

• Protein loading: Load 20-30 μg of total protein per lane.

• Electrophoresis and transfer: Use standard SDS-PAGE (10-12% gels) followed by transfer to PVDF or nitrocellulose membranes.

• Blocking: Block membranes with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Incubate with anti-PDSS2 antibody at 0.4 μg/mL concentration (for ab251797) . Optimize incubation conditions (typically overnight at 4°C).

• Detection: Use appropriate HRP-conjugated secondary antibodies and ECL detection systems.

• Band interpretation: Expect a band at approximately 44 kDa, which is the predicted molecular weight of PDSS2 . Be aware that post-translational modifications or alternative splicing variants (such as PDSS2-Del2) may result in additional bands .

How can researchers accurately detect the PDSS2-Del2 variant?

The PDSS2-Del2 variant, characterized by deletion of exon 2, requires specialized detection methods:

• RNA-level detection: For specific detection of the PDSS2-Del2 splice variant, design primers spanning the exon 1-3 junction (skipping exon 2). Quantitative PCR using SYBR Green can effectively detect this variant .

• In situ hybridization: The BaseScope™ detection system has been successfully used to visualize single molecules of PDSS2-Del2 in tissue microarrays. This technique employs specific probes designed to recognize the exon 1-3 junction unique to this variant .

• Validation controls: Always validate detection specificity using positive and negative controls. The BaseScope™ probe for PDSS2-Del2 has been validated with appropriate controls .

• Quantification: For prognostic purposes, PDSS2-Del2 positivity has been defined as ≥30 signal points per tissue dot in BaseScope™ assays .

• Statistical analysis: Detection data should be subjected to appropriate statistical tests, such as Pearson's Chi-square test for clinical correlations and Kaplan-Meier analysis for survival comparisons .

How can PDSS2 antibodies be used to study cancer progression mechanisms?

PDSS2 antibodies can be instrumental in elucidating cancer progression mechanisms through several sophisticated approaches:

• Expression correlation with malignancy grades: Immunohistochemistry using PDSS2 antibodies has demonstrated that PDSS2 is downregulated in poorly differentiated cancer samples compared to well-differentiated tumors, particularly in hepatocellular carcinoma (HCC). This allows researchers to investigate correlations between PDSS2 expression levels and tumor differentiation status .

• Prognostic biomarker development: Studies have shown that reduced PDSS2 expression is negatively associated with HCC progression, suggesting its potential as a prognostic biomarker. Consistent immunostaining protocols with PDSS2 antibodies can be developed to assess patient prognosis in clinical settings .

• Molecular mechanism investigations: Through combined immunoblotting and functional assays, researchers have discovered that PDSS2 overexpression dramatically suppresses cell proliferation and colony formation while inducing apoptosis in HepG2 cells by triggering G1-phase cell-cycle arrest. PDSS2 antibodies are essential for confirming protein expression levels in these experimental systems .

• Migration and invasion studies: PDSS2 antibodies can be used to confirm protein expression in studies examining cell migration and invasion capabilities, where PDSS2 overexpression has been shown to significantly decrease these capabilities in cancer cells .

• Splice variant differential detection: Unlike full-length PDSS2 (PDSS2-FL) which functions as a tumor suppressor, the PDSS2-Del2 variant promotes tumor cell metastasis and angiogenesis. Specialized detection methods using appropriate antibodies or nucleic acid probes can help distinguish these variants and their contrasting roles in cancer biology .

What approaches can resolve contradictory findings about PDSS2 function in different cancer types?

Resolving contradictory findings about PDSS2 function across cancer types requires sophisticated experimental approaches:

How can PDSS2 antibodies be used in studies of mitochondrial function and CoQ10 biosynthesis?

PDSS2 antibodies are valuable tools for investigating mitochondrial function and CoQ10 biosynthesis pathways:

• Subcellular localization studies: Use immunofluorescence with PDSS2 antibodies to determine the precise subcellular localization of PDSS2 in relation to mitochondria and other organelles. This helps elucidate how PDSS2 participates in the CoQ10 biosynthetic pathway within the cellular architecture .

• Protein-protein interaction analysis: Employ PDSS2 antibodies in co-immunoprecipitation (co-IP) experiments to identify interaction partners within the CoQ10 biosynthetic machinery. This approach can reveal how PDSS2 functions within multiprotein complexes to generate the isoprenoid side chain of ubiquinone.

• Enzymatic activity correlation: Correlate PDSS2 protein levels (detected via antibodies) with enzymatic activity measurements of trans-prenyl transferase to understand structure-function relationships in different physiological or pathological contexts.

• Respiratory chain function assessment: Since PDSS2 may regulate mitochondrial respiratory chain function , researchers can use PDSS2 antibodies to monitor protein levels while simultaneously measuring respiratory chain complex activities, oxygen consumption rates, or ATP production.

• Developmental biology applications: Given PDSS2's potential role in cerebellar development , immunohistochemistry with PDSS2 antibodies can track expression patterns throughout developmental stages in neural tissues to correlate with mitochondrial maturation.

What are common issues when working with PDSS2 antibodies and how can they be resolved?

Researchers commonly encounter several technical challenges when working with PDSS2 antibodies:

• Non-specific banding in Western blots:

  • Problem: Additional bands beyond the expected 44 kDa band for PDSS2.

  • Solution: Optimize blocking conditions (try 5% BSA instead of milk), increase washing stringency, and titrate antibody concentration. Consider that some bands may represent legitimate splice variants like PDSS2-Del2 .

• Weak or absent signal in IHC:

  • Problem: Poor or no staining despite known PDSS2 expression.

  • Solution: Optimize antigen retrieval methods (try different pH buffers and retrieval times), adjust antibody concentration, and extend incubation time. For paraffin sections, a 1/200 dilution has been effective for some PDSS2 antibodies .

• Background staining in immunofluorescence:

  • Problem: High background interfering with specific signal detection.

  • Solution: For U-251 MG cells, 4 μg/ml concentration has produced good results with PFA fixation and Triton X-100 permeabilization . Optimize blocking (try different sera or BSA concentrations) and include appropriate controls.

• Inconsistent results between experiments:

  • Problem: Variable staining intensity or patterns between replicates.

  • Solution: Standardize protocols rigorously, including sample preparation, fixation time, antibody lot, and detection reagents. Consider switching from polyclonal to monoclonal antibodies for more consistent results .

• Species cross-reactivity issues:

  • Problem: Antibody doesn't work in your model organism despite claimed reactivity.

  • Solution: Verify sequence homology between your species and the immunogen used to generate the antibody. Some antibodies are generated against specific regions (e.g., aa 300 to C-terminus of human PDSS2) .

How can researchers validate PDSS2 antibody specificity for their experimental system?

Thorough validation of PDSS2 antibody specificity is essential for experimental reliability:

• Positive and negative control samples:

  • Utilize cell lines with known PDSS2 expression (positive controls: NIH/3T3, RT4, U-251 MG)

  • Include samples where PDSS2 expression is absent or minimal (negative controls)

  • For PDSS2-Del2 specific detection, validate probes with appropriate positive and negative controls as demonstrated in previous studies

• Knockdown/knockout validation:

  • Perform siRNA or CRISPR-based knockdown/knockout of PDSS2

  • Confirm reduced/absent signal with your antibody following knockdown/knockout

  • This represents the gold standard for antibody specificity validation

• Overexpression validation:

  • Transiently overexpress PDSS2 in appropriate cell lines

  • Confirm increased signal intensity in Western blot or immunostaining

  • Include empty vector controls for comparison

• Peptide competition assays:

  • Pre-incubate the antibody with excess immunogenic peptide

  • Apply this mixture to your samples in parallel with untreated antibody

  • Specific signals should be blocked in the peptide-competed samples

• Multiple antibody correlation:

  • Test multiple antibodies targeting different epitopes of PDSS2

  • Compare staining patterns and quantitative results

  • Consistent results across different antibodies increase confidence in specificity

How do expression patterns of PDSS2 and its variants correlate with cancer prognosis?

Research has revealed significant correlations between PDSS2 expression patterns and cancer prognosis:

• Potential as biomarkers:

  • The contrasting roles of full-length PDSS2 and PDSS2-Del2 highlight the importance of isoform-specific detection in prognostic evaluations

  • Researchers should consider both variants when developing PDSS2-based prognostic biomarkers

What experimental approaches can effectively study PDSS2's role in cancer cell migration and invasion?

To effectively investigate PDSS2's role in cancer cell migration and invasion, researchers should employ these methodological approaches:

• Transwell migration and invasion assays:

  • Seed cells (with PDSS2 overexpression or knockdown) in serum-free medium in chambers with 8-μm microporous filters

  • Use medium containing 10% FBS as a chemoattractant

  • After 24 hours, fix and stain cells with crystal violet

  • Count migrated cells to quantify migration capacity

  • For invasion assays, coat filters with Matrigel before seeding cells

• Genetic modification approaches:

  • Create stable cell lines with PDSS2 overexpression or knockdown using appropriate vectors

  • Separately manipulate full-length PDSS2 and PDSS2-Del2 to distinguish their functions

  • Validate expression changes at both RNA level (qPCR) and protein level (Western blot)

• Wound healing assay:

  • Create a "wound" in a confluent cell monolayer

  • Monitor and quantify the rate of wound closure over time

  • Compare PDSS2-manipulated cells with appropriate controls

• Molecular mechanism investigations:

  • Examine epithelial-mesenchymal transition (EMT) markers in PDSS2-modified cells

  • Investigate the relationship between PDSS2-Del2, fumarate levels, and NF-κB pathway activation

  • Consider testing potential therapeutic approaches, such as dimethyl fumarate (DMF), which might counteract the effects of PDSS2-Del2

• In vivo metastasis models:

  • Establish xenograft models using PDSS2-modified cancer cells

  • Monitor primary tumor growth and distant metastasis formation

  • Perform histological analysis of primary and metastatic lesions

How can researchers integrate PDSS2 studies with investigations of mitochondrial dysfunction in cancer?

Integrating PDSS2 studies with mitochondrial dysfunction research in cancer requires multifaceted approaches:

• CoQ10 biosynthesis and mitochondrial function:

  • PDSS2 catalyzes essential steps in the production of prenyl diphosphates, the precursors for CoQ10 side chains

  • Measure CoQ10 levels in cancer cells with altered PDSS2 expression using HPLC-MS

  • Correlate CoQ10 content with mitochondrial respiratory complex activities, particularly Complex I and Complex II which directly use CoQ10

• Metabolic reprogramming assessment:

  • Evaluate how PDSS2 alterations affect metabolic profiles using metabolomics

  • Measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) using Seahorse technology

  • Determine if PDSS2 depletion shifts metabolism toward glycolysis, a common feature in cancer

• Reactive oxygen species (ROS) production:

  • Since CoQ10 is an important antioxidant, measure ROS levels in cells with altered PDSS2 expression

  • Use fluorescent probes such as DCFDA for general ROS or MitoSOX for mitochondrial superoxide

  • Correlate ROS levels with cellular outcomes such as proliferation, migration, and apoptosis

• Mitochondrial dynamics:

  • Investigate how PDSS2 affects mitochondrial morphology, fusion/fission, and mitophagy

  • Use live-cell imaging with mitochondrial-targeted fluorescent proteins or dyes

  • Quantify mitochondrial network parameters including size, interconnectivity, and distribution

• Therapeutic targeting potential:

  • The finding that dimethyl fumarate (DMF) might treat metastasis in HCC patients with elevated PDSS2-Del2 suggests a connection between PDSS2, fumarate metabolism, and mitochondrial function

  • Test CoQ10 supplementation as a potential intervention in cancers with PDSS2 dysfunction

  • Investigate synergies between mitochondria-targeted therapies and conventional cancer treatments in the context of PDSS2 expression patterns

By integrating these approaches, researchers can build a comprehensive understanding of how PDSS2 connects mitochondrial function to cancer biology, potentially identifying new therapeutic strategies targeting this intersection.

What are emerging technologies that might enhance PDSS2 antibody applications in research?

Several emerging technologies show promise for enhancing PDSS2 antibody applications:

• Single-cell protein analysis: Technologies like mass cytometry (CyTOF) and single-cell Western blotting could allow researchers to examine PDSS2 expression heterogeneity at the single-cell level within tumors, potentially revealing subpopulations with different prognoses or therapeutic responses.

• Spatial transcriptomics combined with immunohistochemistry: Integrating PDSS2 antibody staining with spatial transcriptomics could reveal how PDSS2 expression correlates with specific transcriptional programs in different regions of tumors or tissues.

• Super-resolution microscopy: Techniques such as STORM, PALM, or SIM could provide nanoscale resolution of PDSS2 localization within mitochondria and its potential colocalization with other proteins in the CoQ10 biosynthetic pathway.

• Proximity labeling proteomics: Methods like BioID or APEX2 could identify proteins in close proximity to PDSS2 in living cells, revealing novel interaction partners and functional complexes.

• Multiplexed tissue imaging: Technologies allowing simultaneous detection of multiple proteins (such as Imaging Mass Cytometry or Multiplexed Ion Beam Imaging) could enable researchers to analyze PDSS2 expression alongside numerous other cancer biomarkers within the spatial context of intact tissues.

These technologies would significantly advance our understanding of PDSS2's role in normal physiology and disease, particularly in cancer biology where both tumor-suppressive and tumor-promoting variants have been identified .

How might the study of PDSS2 contribute to personalized medicine approaches in cancer?

The study of PDSS2 has significant potential to contribute to personalized medicine approaches in cancer:

• Prognostic stratification: The contrasting roles of full-length PDSS2 (tumor suppressor) and PDSS2-Del2 (promotes metastasis) create an opportunity for more nuanced patient stratification. Patients could be categorized based on expression patterns of these variants, with PDSS2-Del2 positive patients potentially requiring more aggressive treatment approaches .

• Predictive biomarkers: Research suggests PDSS2 variant expression may predict response to specific therapies. For instance, patients with elevated PDSS2-Del2 expression might benefit from therapies targeting the NF-κB pathway or treatment with dimethyl fumarate (DMF) .

• Therapeutic target identification: Understanding the molecular mechanisms by which PDSS2 variants influence cancer progression could reveal novel therapeutic targets. For example, if PDSS2-Del2 promotes cancer through specific molecular pathways, inhibitors of these pathways might be effective in PDSS2-Del2-positive tumors.

• Metabolic vulnerabilities: Since PDSS2 plays a crucial role in CoQ10 biosynthesis and mitochondrial function , tumors with altered PDSS2 expression might exhibit specific metabolic vulnerabilities that could be therapeutically exploited. This connects to the growing field of cancer metabolism as a therapeutic target.

• Monitoring disease progression: Serial assessment of PDSS2 variant expression in liquid biopsies could potentially serve as a minimally invasive method to monitor disease progression and treatment response, allowing for timely adjustments to therapeutic strategies.